• Alvotech’s third-quarter adjusted EBITDA more than doubled year over year to USD 31.5 million.
• Nine-month adjusted revenue fell 23% year over year to USD 323.4 million.
• FDA clearances expanded Simlandi manufacturing capacity in Reykjavík, including a process that more than doubles output per batch.
• Full-year 2026 guidance remains unchanged, with performance now expected toward the lower end of the ranges.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611111615PRIMZONEFULLFEED1001303147) on November 11, 2026, and is solely responsible for the information contained therein.